Curated News
By: NewsRamp Editorial Staff
April 23, 2025
Calidi Biotherapeutics Appoints Eric Poma, Ph.D., as CEO to Drive Clinical Development
TLDR
- Dr. Poma's appointment as CEO brings 30 years of biotech leadership experience, advancing CLDI's virotherapy platform and clinical development.
- Calidi Biotherapeutics uses stem cell-based platforms to empower the immune system against cancer, enhancing efficacy and patient safety in oncology treatments.
- Calidi's innovative technology targets disseminated solid tumors, potentially preventing metastatic disease and improving patient outcomes, contributing to a better future.
- Dr. Poma, a veteran biotech leader, raised over $250 million and secured strategic partnerships with major companies, driving Calidi's advancements in cancer treatment.
Impact - Why it Matters
This news matters as the appointment of Dr. Poma as CEO of Calidi Biotherapeutics marks a significant milestone in the company's journey towards advancing its innovative virotherapy platform. With his extensive experience and leadership, the company is poised for growth and progress in the field of cancer treatment. This development underscores the importance of effective leadership in driving forward advancements in biotechnology and oncology.
Summary
Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Directors, effective Apr. 22. Dr. Poma brings over 30 years of experience in the biotech industry and will support the company's transition into later-stage clinical development.
As Calidi advances its systemic virotherapy platform and prepares for a dose-escalation trial of CLD-201 in solid tumors, the leadership change is expected to drive the company's growth. Calidi specializes in proprietary technology that empowers the immune system to combat cancer, utilizing stem cell-based platforms for multiple oncology indications.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Calidi Biotherapeutics Appoints Eric Poma, Ph.D., as CEO to Drive Clinical Development
